A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma.
Phase of Trial: Phase III
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MIRACLE
- Sponsors AstraZeneca
- 10 May 2018 Planned number of patients changed from 834 to 666.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.
- 16 Jun 2017 New trial record